Business Description
SpectraCure AB
ISIN : SE0007158118
Total Employee Number:
13Compare
Compare
Traded in other countries / regions
SPEC.Sweden2OK.Germany IPO Date
2015-06-29Description
SpectraCure AB develops treatment planning and laser light dose management for cancer treatment. The Company has developed its software IDOSE, and medical laser devices for the treatment.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.59 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.09 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 3.6 | |||||
3-Year EPS without NRI Growth Rate | -20.6 | |||||
3-Year FCF Growth Rate | -2.3 | |||||
3-Year Book Growth Rate | -29.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 67.07 | |||||
9-Day RSI | 57.99 | |||||
14-Day RSI | 52.15 | |||||
3-1 Month Momentum % | -40.07 | |||||
6-1 Month Momentum % | -49.61 | |||||
12-1 Month Momentum % | -68.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.78 | |||||
Quick Ratio | 1.78 | |||||
Cash Ratio | 1.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.5 | |||||
Shareholder Yield % | -52.37 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -52.69 | |||||
ROA % | -45.38 | |||||
ROIC % | -49.47 | |||||
3-Year ROIIC % | -141.91 | |||||
ROC (Joel Greenblatt) % | -1498.33 | |||||
ROCE % | -51.1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.28 | |||||
Price-to-Tangible-Book | 1.95 | |||||
EV-to-EBIT | -0.25 | |||||
EV-to-EBITDA | -0.58 | |||||
EV-to-FCF | -0.28 | |||||
| Price-to-Net-Current-Asset-Value | 3.9 | |||||
| Price-to-Net-Cash | 3.9 | |||||
Earnings Yield (Greenblatt) % | -381.96 | |||||
FCF Yield % | -151.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SpectraCure AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -0.118 | ||
| Beta | -0.7182 | ||
| 3-Year Sharpe Ratio | -0.84 | ||
| 3-Year Sortino Ratio | -1.25 | ||
| Volatility % | 135.69 | ||
| 14-Day RSI | 52.15 | ||
| 14-Day ATR (kr) | 0.005995 | ||
| 20-Day SMA (kr) | 0.035705 | ||
| 12-1 Month Momentum % | -68.37 | ||
| 52-Week Range (kr) | 0.0302 - 0.24438 | ||
| Shares Outstanding (Mil) | 735.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SpectraCure AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SpectraCure AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-02-19 | In 181 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 83 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | 0.04 (+0.26%) | ||
| General meeting for 2025 | 2026-05-27 13:00 | 0.07 (+0.22%) | ||
| First quarter earnings results for 2026 | 2026-05-27 | 0.07 (+0.22%) | ||
| Annual report for 2025 | 2026-04-21 | 0.05 (+0.29%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-19 | 0.08 (-1.18%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 0.15 (-6.41%) | ||
| Second quarter earnings results for 2025 | 2025-08-15 | 0.13 (+0.74%) | ||
| General meeting for 2024 | 2025-05-30 11:00 | 0.19 (+0.00%) |
Show
Entries
SpectraCure AB Frequently Asked Questions
What is SpectraCure AB(OSTO:SPEC)'s stock price today?
The current price of OSTO:SPEC is kr0.04. The 52 week high of OSTO:SPEC is kr0.24 and 52 week low is kr0.03.
When is next earnings date of SpectraCure AB(OSTO:SPEC)?
The next earnings date of SpectraCure AB(OSTO:SPEC) is 2026-11-13.
Does SpectraCure AB(OSTO:SPEC) pay dividends? If so, how much?
SpectraCure AB(OSTO:SPEC) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Wider Range of Prospective Patients in the UK, Canada and the US for Continued Clinical Study | 2020-06-18 | ||
| A Future Alternative to Hormonal Treatment for Prostate Cancer | 2020-06-16 |
Articles on SpectraCure AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers